It's San Francisco vs. South San Francisco

San Francisco has managed to win the hearts and pocketbooks of some of northern California's new breed of biotech companies. Experts say that the new Mission Bay project--and surrounding blocks of commercial space--is the city's best advantage in the battle to woo biotech companies in the area, most of which are now concentrated in the Peninsula or in East Bay. Epiphany Biosciences counts itself among the converted, along with DiObex and others. It's still only a fledgling cluster, but city officials are hoping to see it flourish.

- here's the report from the San Francisco Chronicle

Related Articles:
New report claims signs of bay area brain drain. Report
Bay area biotechs plan new lobbying strategy. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.